Drug Trial Radar · NCT07146022
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
552
Planned (sponsor's estimate)
Start
Jul 25, 2025
Primary completion
Jun 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Veradermics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).
Conditions
- Androgenetic Alopecia (AGA)
- Androgenetic Alopecia
- AGA
- Female Androgenetic Alopecia
- Hair Loss
Interventions
VDPHL01 QDDrug
VDPHL01 Extended Release (ER) Tablet
PlaceboDrug
Placebo tablet
VDPHL01 BIDDrug
VDPHL01 Extended Release (ER) Tablet
PlaceboDrug
Placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in non-vellus Target Area Hair Counts (TAHC)Time frame: Month 6
- Subjects Evaluation of Treatment BenefitTime frame: Month 6
Locations
71 sites in 1 country. Site status is shown where the registry gives one.
Site 73
Birmingham, Alabama
Site 89
Birmingham, Alabama
Site 77
Phoenix, Arizona
Site 30
Fort Smith, Arkansas
Site 69
Encino, California
Site 2
Fremont, California
Site 64
Manhattan Beach, California
Site 93
Northridge, California
Site 66
Santa Monica, California
Site 34
Sherman Oaks, California
Site 94
Thousand Oaks, California
Site 21
Vista, California
Site 5
Castle Rock, Colorado
Site 24
Greenwood Village, Colorado
Site 17
Aventura, Florida
Site 71
Boca Raton, Florida
Site 86
Coral Gables, Florida
Site 62
Coral Gables, Florida
Site 99
Miami, Florida
Site 54
Ocala, Florida
Site 43
Atlanta, Georgia
Site 90
Sandy Springs, Georgia
Site 31
Boise, Idaho
Site 61
Chicago, Illinois
Site 53
Clarksville, Indiana
Site 15
Indianapolis, Indiana
Site 32
New Albany, Indiana
Site 55
Plainfield, Indiana
Site 27
West Lafayette, Indiana
Site 79
Leawood, Kansas
Site 52
Louisville, Kentucky
Site 41
Baton Rouge, Louisiana
Site 13
Covington, Louisiana
Site 12
Metairie, Louisiana
Site 75
New Orleans, Louisiana
Site 84
Glenn Dale, Maryland
Site 87
Rockville, Maryland
Site 22
Brighton, Massachusetts
Site 80
Chestnut Hill, Massachusetts
Site 59
Quincy, Massachusetts
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.